<DOC>
	<DOC>NCT00400322</DOC>
	<brief_summary>The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue. The investigators' hypothesis states that CMV infection promotes tumor development and disease progression and inhibits immune responses against the tumor.</brief_summary>
	<brief_title>Efficacy and Safety of ValcyteÂ® as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Glioblastoma grade IV Cytomegalovirus detected in tumor At least 90% resection of tumor Decreased kidney function Pregnancy Neutropenia Thrombocytopenia Patient not tolerating the drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>antiviral treatment</keyword>
	<keyword>valganciclovir</keyword>
</DOC>